头孢地尔对PERSEUS研究中多重耐药分离株的活性:MIC与临床结局的关系
PERSEUS研究回顾性分析了西班牙同情用药和早期准入项目中头孢地尔治疗多重耐药革兰阴性菌感染的情况,并对57株分离株进行微生物学评估。头孢地尔总体敏感率为86%,对铜绿假单胞菌(占72%)活性突出;即使感染头孢地尔耐药株并接受单药治疗,仍有患者获得临床治愈,提示部分耐药机制仅影响MIC而未导致临床失败。
要点
- 头孢地尔对PERSEUS研究中多重耐药革兰阴性菌分离株总体敏感率为86%。
- 铜绿假单胞菌占分离株72%,头孢地尔对其活性优于多数对照药物(黏菌素除外)。
- 部分头孢地尔耐药株感染患者单药治疗仍获临床治愈,提示需标准化药敏试验。
核心结论
- 头孢地尔对多重耐药革兰阴性菌尤其是铜绿假单胞菌仍有较好体外活性,但耐药株感染患者单药治疗亦可获临床治愈,提示需标准化药敏试验和更深入的基因型-表型关联研究。
研究设计与样本
- PERSEUS研究为回顾性分析,评估西班牙同情用药和早期准入项目中头孢地尔治疗多重耐药革兰阴性菌感染的57株分离株,并与临床结局关联。
主要发现
- 分离株中铜绿假单胞菌占72%,头孢地尔总体敏感率为86%,优于多数对照药物(黏菌素除外)。
- 商业肉汤微量稀释板与参考方法一致性高,支持其常规应用潜力。
- 耐药分离株中B类金属β-内酰胺酶及铁转运基因突变较为普遍。
- 部分头孢地尔耐药株感染患者接受头孢地尔单药治疗仍获临床治愈。
关键数值与推荐
- 药敏结果按EUCAST 2024标准判读。
- 头孢地尔总体敏感率为86%(57株分离株)。
- 铜绿假单胞菌占分离株72%。
临床怎么用
- 头孢地尔仍是治疗多重耐药革兰阴性菌感染(尤其铜绿假单胞菌)的有前景选择。
- 临床采用头孢地尔应依托经过验证的药敏试验方法并持续开展耐药监测。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The PERSEUS study was a retrospective analysis of cefiderocol use under the compassionate use and early access programmes in Spain for the treatment of MDR Gram-negative infections. We present the microbiological evaluation of 57 isolates collected from this study, along with their correlation to clinical outcomes. METHODS: Cefiderocol susceptibility testing was performed using standard broth microdilution (BMD) in iron-depleted media, commercial BMD panels (UMIC®, ComASP®), gradient MIC strips, and disk diffusion. Results were interpreted according to EUCAST 2024 criteria. WGS was used to characterize β-lactamase genes and mutations in genes implicated in cefiderocol resistance. Patients' clinical charts were reviewed. RESULTS: Most isolates were identified as Pseudomonas aeruginosa (72%). Cefiderocol demonstrated an overall susceptibility rate of 86%, outperforming most comparators except colistin. Commercial BMD devices demonstrated high concordance with the reference method, supporting their potential value for routine use. Molecular analysis revealed a high prevalence of class B metallo-β-lactamases, as well as mutations in iron transport genes, among resistant isolates. Notably, clinical cure was achieved even in patients infected with cefiderocol-resistant isolates treated with cefiderocol monotherapy, suggesting that some putative resistance mechanisms affect the MIC, without necessarily leading to clinical failure. CONCLUSIONS: Positive clinical outcomes in patients infected by cefiderocol-resistant isolates by EUCAST breakpoints highlight the need for standardized susceptibility testing, as well as deeper genotype-phenotype correlation studies. Cefiderocol remains a promising option for treating MDR Gram-negative infections, especially those caused by P. aeruginosa. Its adoption in clinical practice should be supported by validated testing methods and ongoing surveillance.
引用
- Cantón R, García-Castillo M, Hernández-García M, et al. Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes. J Antimicrob Chemother. 2026. PMID: 42186121. doi:10.1093/jac/dkag164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。